Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada | NCT07718139

NCT07718139

Overview

NCT ID: NCT07718139
Lead Sponsor: Bristol-Myers SquibbINDUSTRY
Official Title: Real-World Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
Brief Summary: This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery. It looks at participant characteristics, treatments received before and after surgery, and outcomes such as survival.
Conditions: Non-Small Cell Lung Cancer
Interventions: nivolumab

Status and Timeline

Status: Active, not recruiting
Last Update Posted: Jul 21, 2026Actual
Start Date: Feb 28, 2026Actual
Primary Completion Date: Sep 30, 2026Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Diagnosed with non-small-cell lung cancer (NSCLC) stage IIA to IIIB

Participants aged ≥18 years at time of NSCLC diagnosis

Initiated and received neoadjuvant nivolumab or neoadjuvant phase of perioperative immunotherapy during the patient inclusion period

Documented record of curative surgical resection following receipt of neoadjuvant nivolumab or neoadjuvant phase of perioperative immunotherapy

NSCLC is assessed as resectable by a clinician, surgeon, or multidisciplinary team.

Exclusion Criteria:

• Diagnosis of another primary malignancy (excluding non-melanoma skin cancer) within 5 years prior to NSCLC diagnosis or at any time after diagnosis

Study Plan

Study Type: Observational
Phase: No data available
Enrollment: 300Estimated
Primary Purpose: No data available
Allocation: No data available
Interventional Model: No data available
Masking: No data available

Contacts and Locations

Central Contacts: No data available
Locations: IQVIA

Similar Studies

Participant Group/Arms

Neoadjuvant Phase Only

Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received neoadjuvant immunotherapy prior to surgery but did not initiate adjuvant immunotherapy post-surgery.

Biological: nivolumab

Biological: pembrolizumab

Biological: durvalumab

Perioperative Immunotherapy

Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received immunotherapy before surgery and continued the same immunotherapy after surgery (adjuvant phase).

Biological: nivolumab